GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coegin Pharma (NGM:COEGIN) » Definitions » EV-to-EBITDA

Coegin Pharma (NGM:COEGIN) EV-to-EBITDA : -2.96 (As of May. 19, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Coegin Pharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Coegin Pharma's enterprise value is kr73.79 Mil. Coegin Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was kr-24.94 Mil. Therefore, Coegin Pharma's EV-to-EBITDA for today is -2.96.

The historical rank and industry rank for Coegin Pharma's EV-to-EBITDA or its related term are showing as below:

NGM:COEGIN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.63   Med: -0.07   Max: 0.01
Current: -2.96

During the past 7 years, the highest EV-to-EBITDA of Coegin Pharma was 0.01. The lowest was -3.63. And the median was -0.07.

NGM:COEGIN's EV-to-EBITDA is ranked worse than
100% of 455 companies
in the Biotechnology industry
Industry Median: 10.35 vs NGM:COEGIN: -2.96

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-19), Coegin Pharma's stock price is kr3.90. Coegin Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was kr-607.216. Therefore, Coegin Pharma's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Coegin Pharma EV-to-EBITDA Historical Data

The historical data trend for Coegin Pharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coegin Pharma EV-to-EBITDA Chart

Coegin Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial -0.97 -2.58 -7.45 -2.87 -1.81

Coegin Pharma Quarterly Data
Dec18 Mar19 Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.87 -4.44 -3.18 -2.52 -1.81

Competitive Comparison of Coegin Pharma's EV-to-EBITDA

For the Biotechnology subindustry, Coegin Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coegin Pharma's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coegin Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Coegin Pharma's EV-to-EBITDA falls into.



Coegin Pharma EV-to-EBITDA Calculation

Coegin Pharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=73.789/-24.935
=-2.96

Coegin Pharma's current Enterprise Value is kr73.79 Mil.
Coegin Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-24.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Coegin Pharma  (NGM:COEGIN) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Coegin Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.90/-607.216
=At Loss

Coegin Pharma's share price for today is kr3.90.
Coegin Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-607.216.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Coegin Pharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Coegin Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Coegin Pharma (NGM:COEGIN) Business Description

Traded in Other Exchanges
N/A
Address
Birger Jarlsgatan 18 A, 4th Floor, Stockholm, SWE, 114 34
Coegin Pharma AB is a biotechnology company that focuses on the development of small molecule therapies for the treatment of inflammatory diseases such as cancer and kidney disease.

Coegin Pharma (NGM:COEGIN) Headlines

No Headlines